

# Market Announcement

30 September 2019

---

## Phylogica Limited (ASX: PYC) – Trading Halt

### Description

The securities of Phylogica Limited ('PYC') will be placed in trading halt at the request of PYC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 2 October 2019 or when the announcement is released to the market.

### Issued by

**Daniel Nicholson**

Adviser, Listings Compliance (Perth)

## REQUEST FOR TRADING HALT

By email: [tradinghaltsperth@asx.com.au](mailto:tradinghaltsperth@asx.com.au)

**30 September 2019:**

In accordance with Listing Rule 17.1, Phylogica requests that an immediate trading halt be placed on its securities pending an announcement to the market regarding a proposed strategic partnership that is material to the Company.

The Company anticipates that the trading halt will be lifted on or before market open on Wednesday, 2 October 2019 by provision of an announcement to ASX regarding the proposed partnership.

Phylogica is not aware of any reason why the trading halt should not be granted, nor of any other information relevant to this request.

Yours sincerely



Kevin Hart

Company Secretary

**ENDS**

For further information, please contact:

**INVESTORS**  
Rohan Hockings  
CEO  
[Rohan.hockings@pyctx.com](mailto:Rohan.hockings@pyctx.com)

## **About PYC Therapeutics**

*Phylogica Limited trading as PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.*

## **Forward looking statements**

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

---

Tel: +61 8 6151 0994

[pyctx.com](http://pyctx.com)

**Phylogica Limited trading as PYC Therapeutics**

ACN 098 391 961